Lupin & Mylan NV announce launch of Nepexto in Germany

Lupin Limited and Mylan NV announced the launch of Nepexto, biosimilar etanercept, in the German market.

Nepexto is indicated for the treatment of various ailments. Some of them include moderate to severely active rheumatoid arthritis, juvenile idiopathic arthritis from the age of two years, active and progressive psoriatic arthritis and severe axial spondyloarthritis, moderate to severe plaque psoriasis as well as chronic severe plaque psoriasis in children from the age of six years and also, in adolescents.

Nepexto is approved for all therapeutic indications of the reference product Enbrel. It is available as a solution for injection in a pre-filled pen and a pre-filled syringe.

The data shows a high patient acceptance of the easy-to-handle pre-filled pen. Patients favoured this latex-free device for self-injection, which can lead to an improvement in compliance. Nepexto, with equivalent efficacy and safety to reference product Enbrel®, is an attractive cost-effective treatment alternative that can contribute to sustainable healthcare and treatment options.

The stock of Lupin closed at 978.50, up by 0.68 per cent or Rs 6.65 per share. The intraday high is Rs 985.85 and the intraday low is Rs 964. The 52-week high is 1034.55, while its 52-week low is 505 on BSE.